Physician profile
Carlos Singer
NPI 1285654335
$4,403.32
in general payments reported to CMS, 2019-2025
10 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,591 · 2020: $134 · 2022: $37.06 · 2023: $89.69 · 2024: $450 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485 · Travel and Lodging: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.38 |
| Travel and Lodging | $155.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $3,527.77 | 2019-2020 | |
| Abbvie INC. | $330.91 | 2022-2025 | Botox, Ubrelvy |
| Neurocrine Biosciences, INC. | $300.25 | 2024 | |
| Boston Scientific Corporation | $185.35 | 2019 | |
| Merz Pharmaceuticals, LLC | $28.52 | 2025 | Xeomin, Inbrija |
| Ipsen Biopharmaceuticals, INC | $18.69 | 2025 | Dysport |
| Acadia Pharmaceuticals INC | $11.83 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.